Long-term effects of treatment with alendronate for patients with osteoporosis: Commentary

Nature Clinical Practice Rheumatology

Volumn 3, Issue 8, 2007, Pages 426-427

  Lane, Nancy E ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Center for Healthy Aging   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; GLUCOCORTICOID; PLACEBO;

BONE BIOPSY; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; HUMAN; LONG TERM CARE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

EID: 34547569406     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0555     Document Type: Short Survey

References (4)

1. Black DM et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535-1541
2. Cummings SR et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280: 2077-2082
3. Ensrud KE et al. (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19: 1259-1269
4. Cummings SR et al. (1995) Risk factors for hip fractures in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 23: 767-773